ID

11988

Descrição

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL); ODM derived from: https://clinicaltrials.gov/show/NCT02192021

Link

https://clinicaltrials.gov/show/NCT02192021

Palavras-chave

  1. 30/08/2015 30/08/2015 -
Titular dos direitos

ODM derived from: https://clinicaltrials.gov/show/NCT02192021

Transferido a

30 de agosto de 2015

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility ´T Cell Lymphoma NCT02192021

Eligibility Cutaneous T Cell Lymphoma NCT02192021

Inclusion Criteria
Descrição

Inclusion Criteria

diagnosis of cutaneous t-cell lymphoma (ctcl) based upon a skin biopsy diagnostic of atypical epidermotropism of folliculocentric or epidermotropic t-cells.
Descrição

t-cell lymphoma; diagnosis; cutaneous; biopsy; skin

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0079773
current stage of ia or ib.
Descrição

t stage; current

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0677955
expected survival of greater than or equal to12 months.
Descrição

no code found

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0038952
not be on any other investigational device/drug treatment.
Descrição

treatment; other; device; drug

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C2346570
UMLS CUI [1,2]
C0013230
have a sufficient number (i.e., n=4 for first dose cohort in initial safety evaluation; n=3 for remainder of subjects) and surface area (> 5 cm2) of ctcl patches or plaques for micro needle array-doxorubicin (mna-d) and micro needle array (mna) application.
Descrição

application; doxorubicin; initial; number; cohort; first; dose; area

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013089
willing to adhere to the instructions of the investigator and his research team and sign an informed consent form prior to entry into the study.
Descrição

informed consent; investigator; entry; study

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021430
have the following initial and subsequent pretreatment laboratory parameters: granulocytes ≥2,000/mm3; platelets >50,000/mm3; Serum creatinine level ≤2x the upper limit of normal (uln); ast, alt, , ldh, alk phos ≤3x the uln.subjects must be ³ 18 years of age and must be able to understand the written informed consent/assent document.
Descrição

upper limit of normal (sgpt); upper limit of normal (sgot); >= 18 years of age; informed consent; < 18 years of age; > 18 years of age; serum creatinine; granulocytes; platelets; laboratory; initial; ldh; ast; uln; alt

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0018183
UMLS CUI [2]
C0005821
UMLS CUI [3]
C0600061
UMLS CUI [4]
C0438236
have no evidence of active infection, regardless of the degree of severity or localization. subjects with active infections (whether or not they require antibiotic therapy) may be eligible for study participation after complete resolution of the infection. subjects on antibiotic therapy must be off antibiotics before beginning treatment.
Descrição

antibiotic therapy; active infections; evidence of; treatment; severity; complete; degree; study

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009450
not receive any other treatment for ctcl except emollients of subject's choice without topical steroids, anti-fungal or antibacterial topical preparations.
Descrição

other treatment; anti-fungal; steroids; topical

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2015819
willing to discontinue concomitant medications for ctcl for the duration of their study participation, including: high dose topical steroids - 2 week washout; oral steroids above 10 mg - 3 week washout; psoralen + ultraviolet a light (puva) or ultraviolet b light (uvb) (including sunbathing, tanning beds, etc.) - 2 week washout; extracorporeal photopheresis - 2 week washout; electron beam - 2 weeks washout; chemotherapeutic agents - 3 week washout; bexarotene capsules or other oral biologics - 2 week washout; and topical nitrogen mustard - 2 week washout.
Descrição

concomitant medications; chemotherapeutic agent; steroids; duration; capsules; electron; topical; agents; study; dose; high; oral; puva; week

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2347852
Exclusion Criteria
Descrição

Exclusion Criteria

Exclusion Criteria
Descrição

Exclusion Criteria

uncontrolled pain.
Descrição

pain

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1557623
known history of autoimmune disease; or active hiv, htlv-1, and/or hepatitis infection.
Descrição

autoimmune disease; infection; hepatitis; active; hiv

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2]
C0019158
UMLS CUI [3]
C0019682
pregnant or lactating.
Descrição

pregnant

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2828358
UMLS CUI [2]
C0549206
have sensitivity to drugs that provide local anesthesia.
Descrição

local anesthesia; drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0237865
have active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix.
Descrição

carcinoma in situ; metastatic; prostate; exception; cervix; active; cancer; skin; non

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0006826

Similar models

Eligibility Cutaneous T Cell Lymphoma NCT02192021

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
t-cell lymphoma; diagnosis; cutaneous; biopsy; skin
Item
diagnosis of cutaneous t-cell lymphoma (ctcl) based upon a skin biopsy diagnostic of atypical epidermotropism of folliculocentric or epidermotropic t-cells.
boolean
C0079773 (UMLS CUI [1])
t stage; current
Item
current stage of ia or ib.
boolean
C0677955 (UMLS CUI [1])
no code found
Item
expected survival of greater than or equal to12 months.
boolean
C0038952 (UMLS CUI [1])
treatment; other; device; drug
Item
not be on any other investigational device/drug treatment.
boolean
C2346570 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
application; doxorubicin; initial; number; cohort; first; dose; area
Item
have a sufficient number (i.e., n=4 for first dose cohort in initial safety evaluation; n=3 for remainder of subjects) and surface area (> 5 cm2) of ctcl patches or plaques for micro needle array-doxorubicin (mna-d) and micro needle array (mna) application.
boolean
C0013089 (UMLS CUI [1])
informed consent; investigator; entry; study
Item
willing to adhere to the instructions of the investigator and his research team and sign an informed consent form prior to entry into the study.
boolean
C0021430 (UMLS CUI [1])
upper limit of normal (sgpt); upper limit of normal (sgot); >= 18 years of age; informed consent; < 18 years of age; > 18 years of age; serum creatinine; granulocytes; platelets; laboratory; initial; ldh; ast; uln; alt
Item
have the following initial and subsequent pretreatment laboratory parameters: granulocytes ≥2,000/mm3; platelets >50,000/mm3; Serum creatinine level ≤2x the upper limit of normal (uln); ast, alt, , ldh, alk phos ≤3x the uln.subjects must be ³ 18 years of age and must be able to understand the written informed consent/assent document.
boolean
C0018183 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0600061 (UMLS CUI [3])
C0438236 (UMLS CUI [4])
antibiotic therapy; active infections; evidence of; treatment; severity; complete; degree; study
Item
have no evidence of active infection, regardless of the degree of severity or localization. subjects with active infections (whether or not they require antibiotic therapy) may be eligible for study participation after complete resolution of the infection. subjects on antibiotic therapy must be off antibiotics before beginning treatment.
boolean
C0009450 (UMLS CUI [1])
other treatment; anti-fungal; steroids; topical
Item
not receive any other treatment for ctcl except emollients of subject's choice without topical steroids, anti-fungal or antibacterial topical preparations.
boolean
C2015819 (UMLS CUI [1])
concomitant medications; chemotherapeutic agent; steroids; duration; capsules; electron; topical; agents; study; dose; high; oral; puva; week
Item
willing to discontinue concomitant medications for ctcl for the duration of their study participation, including: high dose topical steroids - 2 week washout; oral steroids above 10 mg - 3 week washout; psoralen + ultraviolet a light (puva) or ultraviolet b light (uvb) (including sunbathing, tanning beds, etc.) - 2 week washout; extracorporeal photopheresis - 2 week washout; electron beam - 2 weeks washout; chemotherapeutic agents - 3 week washout; bexarotene capsules or other oral biologics - 2 week washout; and topical nitrogen mustard - 2 week washout.
boolean
C2347852 (UMLS CUI [1])
pain
Item
uncontrolled pain.
boolean
C1557623 (UMLS CUI [1])
autoimmune disease; infection; hepatitis; active; hiv
Item
known history of autoimmune disease; or active hiv, htlv-1, and/or hepatitis infection.
boolean
C0004364 (UMLS CUI [1])
C0019158 (UMLS CUI [2])
C0019682 (UMLS CUI [3])
pregnant
Item
pregnant or lactating.
boolean
C2828358 (UMLS CUI [1])
C0549206 (UMLS CUI [2])
local anesthesia; drugs
Item
have sensitivity to drugs that provide local anesthesia.
boolean
C0237865 (UMLS CUI [1])
carcinoma in situ; metastatic; prostate; exception; cervix; active; cancer; skin; non
Item
have active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix.
boolean
C0006826 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial